Inactive Instrument

News BioRestorative Therapies, Inc. Other OTC

Equities

BRTX

US0906554086

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	Apr. 16	DJ
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	Apr. 16	MT
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	Apr. 16	AQ
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	Apr. 16	CI
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	Apr. 08	AQ
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	Apr. 08	CI
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	Apr. 03	AQ
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	Apr. 01	AQ
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	Mar. 11	AQ
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	Feb. 14	CI
Top Midday Decliners	Feb. 06	MT
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	Feb. 06	AQ
Top Premarket Decliners	Feb. 06	MT
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise	Feb. 05	MT
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	Feb. 05	AQ
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	Feb. 05	CI
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting	Feb. 01	AQ
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program	Dec. 12	AQ
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioRestorative Therapies, Inc. Other OTC

Equities

BRTX

US0906554086

Summary

Filters